Engineering protein glycosylation in CHO cells to be highly similar to murine host cells

Инженерия гликозилирования белков в клетках CHO для достижения высокой степени сходства с клетками-хозяевами мышиного происхождения
Scott T. Kuhns, James M. Piret, Shivani Gupta, Bhavana Shah, Coral Shek Fung, Pik Kay Chan, Devin L. Wakefield, Chetan T. Goudar, Coral Fung Shek
2023-02-16

CHO cellsCMAH overexpressionGGTA overexpressionbiosimilar monoclonal antibodiesmurine-like glycans
Since 2015 more than 34 biosimilars have been approved by the FDA. This new era of biosimilar competition has stimulated renewed technology development focused on therapeutic protein or biologic manufacturing. One challenge in biosimilar development is the genetic differences in the host cell lines used to manufacture the biologics. For example, many biologics approved between 1994 and 2011 were expressed in murine NS0 and SP2/0 cell lines. Chinese Hamster ovary (CHO) cells, however, have since become the preferred hosts for production due to their increased productivity, ease of use, and stability. Differences between murine and hamster glycosylation have been identified in biologics produced using murine and CHO cells. In the case of monoclonal antibodies (mAbs), glycan structure can significantly affect critical antibody effector function, binding activity, stability, efficacy, and in vivo half-life. In an attempt to leverage the intrinsic advantages of the CHO expression system and match the reference biologic murine glycosylation, we engineered a CHO cell expressing an antibody that was originally produced in a murine cell line to produce murine-like glycans. Specifically, we overexpressed cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) and N-acetyllactosaminide alpha-1,3-galactosyltransferase (GGTA) to obtain glycans with N-glycolylneuraminic acid (Neu5Gc) and galactose-α-1,3-galactose (alpha gal). The resulting CHO cells were shown to produce mAbs with murine glycans, and they were then analyzed by the spectrum of analytical methods typically used to demonstrate analytical similarity as a part of demonstrating biosimilarity. This included high-resolution mass spectrometry, biochemical, as well as cell-based assays. Through selection and optimization in fed-batch cultures, two CHO cell clones were identified with similar growth and productivity criteria to the original cell line. They maintained stable production for 65 population doubling times while matching the glycosylation profile and function of the reference product expressed in murine cells. This study demonstrates the feasibility of engineering CHO cells to express mAbs with murine glycans to facilitate the development of biosimilars that are highly similar to marketed reference products expressed in murine cells. Furthermore, this technology can potentially reduce the residual uncertainty regarding biosimilarity, resulting in a higher probability of regulatory approval and potentially reduced costs and time in development.
1
CHO cells were engineered by overexpressing CMAH and GGTA to produce murine-like Neu5Gc- and alpha-gal-containing glycans.
2
Engineered antibodies were evaluated using high-resolution mass spectrometry, biochemical assays, and cell-based assays relevant to analytical similarity and biosimilarity assessment.
3
The engineered CHO cells produced monoclonal antibodies carrying glycan structures characteristic of murine host cells.
4
The selected clones maintained stable antibody production for 65 population doublings.
5
Two optimized CHO clones achieved growth and productivity comparable to the original production cell line in fed-batch cultures.

CHO cells expressing a monoclonal antibody originally produced in a murine cell line

Engineering and characterization of murine-like antibody glycosylation, including Neu5Gc and alpha-gal glycans, while maintaining comparable cell growth and antibody productivity

Publication Details
Publication Date
2023-02-16
Journal
Publisher
ISSN
Cited by
13
Access Type
Author Information
Authors
Scott T. Kuhns
James M. Piret
Shivani Gupta
Bhavana Shah
Coral Shek Fung
Pik Kay Chan
Devin L. Wakefield
Chetan T. Goudar
Coral Fung Shek
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%